# Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

> **NCT03403205** · PHASE3 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 214 (actual)

## Conditions studied

- Wilson Disease

## Interventions

- **DRUG:** ALXN1840
- **DRUG:** SoC Therapy

## Key facts

- **NCT ID:** NCT03403205
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-22
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 214 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate the program
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403205, "Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03403205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*